EC Number   |
Application |
Reference  |
|---|
   3.4.17.23 | medicine |
potential important target in cardio-renal disease |
657967 |
| 3.4.17.23 | pharmacology |
design and synthesis of first potent and selective enzyme inhibitors may be useful as pharmacological tools to help understanding the biological relevance and potantial role of the enzyme in human disease |
658963 |
| 3.4.17.23 | medicine |
chronic treatment with the AT1R antagonist almesartan induces a fivefold increase in ACE2 mRNA in the aorta which leads to a significant increase in aortic angiotensin(1-7) protein expression. These effects are associated with significant decreases in aortic medial thickness and may represent an important protective mechanism in the prevention of cardiovascular events in hypertensive subjects |
667145 |
| 3.4.17.23 | medicine |
identification of ACE2 as a receptor for SARS-CoV will contribute to the development of antivirals and vaccines |
668221 |
| 3.4.17.23 | medicine |
ACE2 protects against acute lung injury in several animal models of acute respiratory distress syndrome. Increasing ACE2 activity might be a novel approach for the treatment of acute lung failure in several diseases |
668354 |
| 3.4.17.23 | medicine |
angiotensin-converting enzyme 2 is a target for gene therapy for hypertension disorders |
668528 |
| 3.4.17.23 | analysis |
mass spectrometric assay for angiotensin-converting enzyme 2 using angiotensin II as substrate will have applications in drug screening, antagonist development, and clinical investigations |
668895 |
| 3.4.17.23 | medicine |
recombinant ACE2 can protect mice from severe acute lung injury |
670375 |
| 3.4.17.23 | medicine |
ACE-2 protects against lung fibrogenesis by limiting the local accumulation of the profibrotic peptide angiotensin II |
677486 |
| 3.4.17.23 | medicine |
ACE2 is a functional receptor for the causative agent of severe acute repiratory syndrome, the SARS coronavirus, ACE2 also plays a role in the development of liver fibrosis and subsequent cirrhosis |
678102 |
